JP Morgan Chase
OCUL icon

JP Morgan Chase’s Ocular Therapeutix OCUL Stock Holding History

JP Morgan Chase’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.85M Sell
520,663
-29,606
-5% -$282K ﹤0.01% 3564
2025
Q4 		$6.68M Buy
550,269
+274,109
+99% +$3.33M ﹤0.01% 3057
2025
Q3 		$3.23M Sell
276,160
-435,940
-61% -$5.21M ﹤0.01% 3721
2025
Q2 		$6.61M Buy
712,100
+374,269
+111% +$2.93M ﹤0.01% 2902
2025
Q1 		$2.48M Buy
337,831
+148,536
+78% +$1.14M ﹤0.01% 3715
2024
Q4 		$1.62M Buy
189,295
+104,650
+124% +$1.02M ﹤0.01% 4306
2024
Q3 		$736K Sell
84,645
-728
-0.9% -$6K ﹤0.01% 4667
2024
Q2 		$584K Buy
85,373
+16,147
+23% +$99.7K ﹤0.01% 4605
2024
Q1 		$630K Buy
69,226
+1,201
+2% +$8.52K ﹤0.01% 4643
2023
Q4 		$303K Buy
68,025
+148
+0.2% +$438 ﹤0.01% 5100
2023
Q3 		$213K Buy
67,877
+3,766
+6% +$15.4K ﹤0.01% 5037
2023
Q2 		$331K Buy
64,111
+170
+0.3% +$1.01K ﹤0.01% 4752
2023
Q1 		$337K Buy
63,941
+17,838
+39% +$84.7K ﹤0.01% 4736
2022
Q4 		$130K Sell
46,103
-1,444
-3% -$4.78K ﹤0.01% 5240
2022
Q3 		$198K Buy
47,547
+3,320
+8% +$16.7K ﹤0.01% 4962
2022
Q2 		$178K Sell
44,227
-1,027
-2% -$3.88K ﹤0.01% 5137
2022
Q1 		$224K Buy
45,254
+8,439
+23% +$46.8K ﹤0.01% 5130
2021
Q4 		$257K Buy
36,815
+2,748
+8% +$21.3K ﹤0.01% 5214
2021
Q3 		$340K Buy
34,067
+868
+3% +$9.75K ﹤0.01% 4941
2021
Q2 		$471K Sell
33,199
-7,105
-18% -$108K ﹤0.01% 4732
2021
Q1 		$661K Sell
40,304
-41,576
-51% -$801K ﹤0.01% 4506
2020
Q4 		$1.7M Sell
81,880
-146,158
-64% -$2.17M ﹤0.01% 3597
2020
Q3 		$1.78M Buy
228,038
+210,794
+1,222% +$1.75M ﹤0.01% 3314
2020
Q2 		$144K Buy
17,244
+3,750
+28% +$24.9K ﹤0.01% 4415
2020
Q1 		$67K Sell
13,494
-99
-0.7% -$489 ﹤0.01% 4643
2019
Q4 		$54K Hold
13,593
– – ﹤0.01% 5104
2019
Q3 		$41K Sell
13,593
-279,354
-95% -$1.25M ﹤0.01% 5243
2019
Q2 		$1.29M Buy
292,947
+275,307
+1,561% +$1.02M ﹤0.01% 3684
2019
Q1 		$70K Buy
17,640
+9,110
+107% +$36.6K ﹤0.01% 5003
2018
Q4 		$34K Sell
8,530
-44,134
-84% -$243K ﹤0.01% 5194
2018
Q3 		$362K Sell
52,664
-22,848
-30% -$143K ﹤0.01% 4438
2018
Q2 		$509K Buy
75,512
+69,707
+1,201% +$479K ﹤0.01% 4165
2018
Q1 		$38K Sell
5,805
-21,022
-78% -$118K ﹤0.01% 4903
2017
Q4 		$119K Sell
26,827
-305,873
-92% -$1.56M ﹤0.01% 4594
2017
Q3 		$2.13M Sell
332,700
-5,800
-2% -$37.3K ﹤0.01% 3117
2017
Q2 		$3.14M Sell
338,500
-27,325
-7% -$264K ﹤0.01% 2778
2017
Q1 		$3.39M Buy
+365,825
New +$3.05M ﹤0.01% 2694

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

JP Morgan Chase's OCUL Position: Q1 2026 in Review

JP Morgan Chase reduced its Ocular Therapeutix (OCUL) stake by 5.4% in Q1 2026, selling an estimated $282K and leaving 520,663 shares worth $3.85M. The position accounts for ﹤0.01% of the portfolio, ranked #3564.

JP Morgan Chase first reported a position in OCUL in Q1 2017 and has held it in 37 quarters since. The position peaked at $6.68M in Q4 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • JP Morgan Chase held 520,663 shares of Ocular Therapeutix worth $3.85M as of Q1 2026.
  • JP Morgan Chase sold 29,606 Ocular Therapeutix shares in Q1 2026, an estimated $282K.
  • Ocular Therapeutix made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3564 holding.
  • JP Morgan Chase first reported a position in Ocular Therapeutix in Q1 2017 and has held it in 37 quarters since.
  • JP Morgan Chase's Ocular Therapeutix position peaked at $6.68M in Q4 2025.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.